Samelisant

DB14835InvestigationalSmall molecule

SUVN-G3031 is under investigation in clinical trial NCT02342041 (A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects).

Mechanism: Pharmacologically active on Histamine H3 receptor
Curator reviewed
Formula / weight: C₂₁H₃₁N₃O₃ · 373.497 g/mol (avg)
Code names: SUVN-G3031

Resolves to

Compound

UNII65V47O9NOPCAS1394808-82-2

Structure

InChIKeyLNXDUSQEXVQFGP-UHFFFAOYSA-NSMILESO=C(CN1CCOCC1)NC1=CC=C(OC2CCN(CC2)C2CCC2)C=C1

Targets

Q9Y5N1HRH3

What you can answer from here — as of September 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Samelisant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account